Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL: Imiquimod vs Radiotherapy for Lentigo Maligna
NCT02394132Phase 3Completed
- Start
- Aug 2015
- Primary completion
- Dec 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of imiquimod in lentigo maligna (LM) (2 arms). Primary endpoint: Proportion of patients experiencing LM treatment failure at 6 months. Started Aug 2015; status: completed.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on NCT02394132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394132.